Business Wire

Cloud4C Recognized as Microsoft Azure Expert Managed Service Provider

Share

Cloud4C, a Global Cloud Managed Services Provider, announced that it has achieved Microsoft Azure Expert Managed Services Provider status from Microsoft.

Cloud4C is one of the latest Cloud Managed Services Providers globally to be recognized as an Azure Expert MSP. The Azure Expert MSP recognition credits a cloud solution provider who has proven expertise and differentiation in the marketplace showcasing capabilities across Azure services in helping customers navigate cloud landscape efficiently.

Cloud4C was recognized as an Azure Expert MSP based on the company’s expertise across datacenter modernization services, cloud migration and managed services, SAP hosting services, business continuity, advisory services, advanced security management techniques, and constant improvement methodologies for Azure clients.

Cloud4C will continue to deepen its collaboration with Microsoft to deliver end-to-end services to enable enterprises to migrate and manage workloads on Azure. With this collaboration, Cloud4C’s Migration factory built for Azure will help enterprises in modernizing their applications and Databases seamlessly to the cloud. With specialized skills for OpenSource databases like PostgreSQL, MariaDB, MySQL, etc., customized commercial database management services are enabling enterprises to transform on a cost-effective model while providing flexibility and agility to the clients’ IT eco-system.

Sridhar Pinnapureddy, Founder & CEO at Cloud4C, said, "Our latest achievement is a testament to the depth of our Microsoft expertise and capabilities. We are committed to delivering value-based business outcomes by staying true to our ‘Total Ownership Philosophy’ and helping enterprises seamlessly deploy and manage workloads on Microsoft Azure. Our deep technical expertise as a certified Azure Expert MSP allows customers to focus on their core business functions and trust us with managing the intricacies of cloud.”

Gavriella Schuster, Corporate Vice President, One Commercial Partner, Microsoft Corp. said, “We developed the Microsoft Azure Expert Managed Service Provider program to validate and recognize our most accomplished and qualified partners to drive growth for customers. With this recognition, Cloud4C has demonstrated their expertise and commitment to deliver premium managed services on Azure.”

With 600+ Azure Certified professionals and serving 3500+ enterprises on cloud, Cloud4C is enabling customers to achieve seamless digital cloud journeys with specialized solution offering across SAP core Banking, E-commerce, Big Data & analytics, Cyber security, Open Source Databases, AI/ML, Hybrid Cloud, Devops, Automation, IOT, Blockchain and App Modernization on Azure.

ABOUT CLOUD4C

Cloud4C is a preferred Cloud Evolution Partner to 3500 enterprises including 60 of Fortune 500 companies’. Cloud4C has over 1800 certified experts with presence across 25 countries managing mission critical workloads across public, private and hybrid cloud platforms. Cloud4C has delivered 1 billion managed services hours with experience in migrating and managing more than 25000 applications and databases on to cloud powered by AIOps and 24X7 ML enabled monitoring.

For more information, log onto https://www.cloud4c.com

Contact information

Samuel Varghese | Cloud4C | press@cloud4c.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy17.1.2021 00:15:00 EETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 11:00:00 EETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 09:30:00 EETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 23:58:00 EETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 21:15:00 EETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

Tigo Energy Raises $20 Million in Funding14.1.2021 19:33:00 EETPress release

Tigo Energy, Inc., the worldwide leader in Flex-MLPE (Module Level Power Electronics) today announced a $20 million round of investment, led by Energy Growth Momentum. “2020 has been a breakout year for Tigo and 2021 has the potential for even greater success,” stated Zvi Alon, Chairman and CEO of Tigo. “We are excited to have the EG Momentum team’s support and their working capital will enable us to better serve our current customer base and invest in the future expansion with new customers, new partners and new projects.” The investment will be used to improve upon existing products and develop next generation solutions that maximize returns for PV customers. A portion of the new funds will be used to efficiently and effectively scale. Tigo’s growth has accelerated significantly recently as the company’s products have reached more customer segments and countries throughout the world. With over 40,000 installations in over 100 countries on all 7 continents, Tigo systems generate more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom